SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Pharmova - Quaterly Results

03 Feb 2023 Evaluate
The company witnessed a 17.54% growth in the revenue at Rs. 1827.40 millions for the quarter ended December 2022 as compared to Rs. 1554.70 millions during the year-ago period.The Net Loss for the quarter ended December 2022 is Rs. -58.90 millions as compared to Net Loss of Rs. -156.00 millions of corresponding quarter ended December 2021 Operating profit Margin for the quarter ended December 2022 improved to 59.80% as compared to -92.70% of corresponding quarter ended December 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 1827.40 1554.70 17.54 6102.80 4850.40 25.82 877.50 27095.00 -96.76
Other Income 78.70 85.50 -7.95 1242.30 1189.50 4.44 1258.70 478.80 162.89
PBIDT 59.80 -92.70 -164.51 1252.70 1051.10 19.18 1190.90 4749.40 -74.93
Interest 55.30 27.40 101.82 128.20 80.70 58.86 305.90 1018.00 -69.95
PBDT 4.50 -120.10 -103.75 1124.50 970.40 15.88 885.00 3731.40 -76.28
Depreciation 115.90 92.30 25.57 318.80 276.50 15.30 62.50 999.70 -93.75
PBT -111.40 -212.40 -47.55 805.70 693.90 16.11 822.50 2731.70 -69.89
TAX -52.50 -56.40 -6.91 -1.70 -6.40 -73.44 37.50 586.90 -93.61
Deferred Tax -52.30 -37.90 37.99 -145.50 -149.30 -2.55 -99.10 132.50 -174.79
PAT -58.90 -156.00 -62.24 807.40 700.30 15.29 785.00 2144.80 -63.40
Equity 159.30 159.30 0.00 159.30 159.30 0.00 159.30 159.30 0.00
PBIDTM(%) 3.27 -5.96 -154.88 20.53 21.67 -5.28 135.72 17.53 674.25

Jubilant Pharmova Share Price

911.60 6.55 (0.72%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×